Gland Pharma Limited (GLAND) - Net Assets
Based on the latest financial reports, Gland Pharma Limited (GLAND) has net assets worth Rs95.63 Billion INR (≈ $1.03 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs118.00 Billion ≈ $1.28 Billion USD) and total liabilities (Rs22.37 Billion ≈ $241.96 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Gland Pharma Limited to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs95.63 Billion |
| % of Total Assets | 81.04% |
| Annual Growth Rate | 20.27% |
| 5-Year Change | 55.01% |
| 10-Year Change | N/A |
| Growth Volatility | 16.72 |
Gland Pharma Limited - Net Assets Trend (2017–2025)
This chart illustrates how Gland Pharma Limited's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Gland Pharma Limited for the complete picture of this company's asset base.
Annual Net Assets for Gland Pharma Limited (2017–2025)
The table below shows the annual net assets of Gland Pharma Limited from 2017 to 2025. For live valuation and market cap data, see GLAND market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs91.51 Billion ≈ $989.62 Million |
+4.89% |
| 2024-03-31 | Rs87.24 Billion ≈ $943.45 Million |
+9.61% |
| 2023-03-31 | Rs79.59 Billion ≈ $860.71 Million |
+11.19% |
| 2022-03-31 | Rs71.58 Billion ≈ $774.07 Million |
+21.25% |
| 2021-03-31 | Rs59.03 Billion ≈ $638.41 Million |
+61.90% |
| 2020-03-31 | Rs36.46 Billion ≈ $394.33 Million |
+27.40% |
| 2019-03-31 | Rs28.62 Billion ≈ $309.51 Million |
+18.74% |
| 2018-03-31 | Rs24.10 Billion ≈ $260.67 Million |
+15.34% |
| 2017-03-31 | Rs20.90 Billion ≈ $226.01 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Gland Pharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 359.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs71.57 Billion | 78.21% |
| Common Stock | Rs164.76 Million | 0.18% |
| Other Comprehensive Income | Rs412.28 Million | 0.45% |
| Other Components | Rs19.36 Billion | 21.16% |
| Total Equity | Rs91.51 Billion | 100.00% |
Gland Pharma Limited Competitors by Market Cap
The table below lists competitors of Gland Pharma Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
$3.12 Billion |
|
TVS Holdings Limited
NSE:TVSHLTD
|
$3.12 Billion |
|
Beijing Vantone Real Estate Co Ltd
SHG:600246
|
$3.12 Billion |
|
Empresas CMPC
SN:CMPC
|
$3.12 Billion |
|
Rev Group Inc
NYSE:REVG
|
$3.12 Billion |
|
Erasca Inc
NASDAQ:ERAS
|
$3.12 Billion |
|
CRRC Corporation Limited
F:C2L
|
$3.12 Billion |
|
Marathon Digital Holdings Inc
NASDAQ:MARA
|
$3.12 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gland Pharma Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 87,238,430,000 to 91,507,410,000, a change of 4,268,980,000 (4.9%).
- Net income of 6,985,260,000 contributed positively to equity growth.
- Dividend payments of 3,294,880,000 reduced retained earnings.
- New share issuances of 24,880,000 increased equity.
- Other comprehensive income increased equity by 509,330,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs6.99 Billion | +7.63% |
| Dividends Paid | Rs3.29 Billion | -3.6% |
| Share Issuances | Rs24.88 Million | +0.03% |
| Other Comprehensive Income | Rs509.33 Million | +0.56% |
| Other Changes | Rs44.39 Million | +0.05% |
| Total Change | Rs- | 4.89% |
Book Value vs Market Value Analysis
This analysis compares Gland Pharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.15x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 12.98x to 3.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | Rs134.87 | Rs1750.80 | x |
| 2018-03-31 | Rs155.56 | Rs1750.80 | x |
| 2019-03-31 | Rs184.71 | Rs1750.80 | x |
| 2020-03-31 | Rs235.32 | Rs1750.80 | x |
| 2021-03-31 | Rs372.97 | Rs1750.80 | x |
| 2022-03-31 | Rs435.01 | Rs1750.80 | x |
| 2023-03-31 | Rs483.28 | Rs1750.80 | x |
| 2024-03-31 | Rs529.57 | Rs1750.80 | x |
| 2025-03-31 | Rs555.45 | Rs1750.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gland Pharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.63%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.44%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 1.23x
- Recent ROE (7.63%) is below the historical average (14.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 19.80% | 27.97% | 0.60x | 1.18x | Rs2.05 Billion |
| 2018 | 13.32% | 19.82% | 0.55x | 1.22x | Rs800.15 Million |
| 2019 | 15.79% | 22.10% | 0.58x | 1.23x | Rs1.66 Billion |
| 2020 | 21.20% | 29.35% | 0.64x | 1.12x | Rs4.08 Billion |
| 2021 | 16.89% | 28.79% | 0.53x | 1.10x | Rs4.07 Billion |
| 2022 | 16.93% | 27.53% | 0.56x | 1.09x | Rs4.96 Billion |
| 2023 | 9.81% | 21.55% | 0.41x | 1.10x | Rs-148.29 Million |
| 2024 | 8.85% | 13.64% | 0.53x | 1.22x | Rs-999.24 Million |
| 2025 | 7.63% | 12.44% | 0.50x | 1.23x | Rs-2.17 Billion |
Industry Comparison
This section compares Gland Pharma Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $23,713,303,062
- Average return on equity (ROE) among peers: 8.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gland Pharma Limited (GLAND) | Rs95.63 Billion | 19.80% | 0.23x | $3.12 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $988.60 Million | 6.59% | 1.36x | $27.93 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $6.52 Billion | 21.67% | 1.42x | $371.43 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $19.90 Billion | 13.69% | 0.46x | $725.68 Million |
| Abbott India Limited (ABBOTINDIA) | $36.99 Billion | 32.48% | 0.40x | $5.85 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.16 Billion | 12.69% | 1.32x | $3.81 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $6.25 Billion | -40.39% | 3.91x | $906.19 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $6.98 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.46 Billion | 16.82% | 0.29x | $178.52 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $51.90 Billion | 11.24% | 0.50x | $1.60 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $23.50 Billion | -5.26% | 1.65x | $8.73 Billion |
About Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic … Read more